Studies uncover findings on antibody responses, immunity
Findings from two studies add to a growing body of knowledge that is essential for guiding public health initiatives and might one day enable clinicians to assess individuals’ immunity to SARS-CoV-2, according to AACC. Read More
New DNA editing tool could enable more personalized cell therapies
University of Minnesota, Twin Cities researchers have developed a new tool to predict and customize the rate of a type of DNA editing called site-specific recombination, offering the potential for more personalized cell therapies. Read More
CRISPR reveals interconnected map of immune feedback loops, regulatory networks
The disruption of thousands of genes using CRISPR-Cas9 gene editing has revealed a map of how human immune cells function. The resulting map could reveal the collections of genes that need to function properly to prevent immune diseases. Read More
MASTER technology could transform CAR T-cell therapy
A new technology that helps CAR T cells attack cancer cells more aggressively than conventional methods has been published by researchers from North Carolina. Called multifunctional alginate scaffold for T-cell engineering and release (MASTER), the technology was described in a paper published on March 24 in Nature Biotechnology. Read More
PerkinElmer highlights new workflows at SLAS 2022
BOSTON - Following a series of acquisitions of Horizon Discovery, BioLegend, Nexcelom Bioscience, and Omni International in 2021, PerkinElmer showcased end-to-end life sciences workflows at the Society for Laboratory Automation and Screening (SLAS) 2022 International Conference and Expo. Read More
Bio-Rad develops antidaratumumab antibodies for drug monitoring
Bio-Rad Laboratories has launched a range of antidaratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars, according to the company. Read More
IsoPlexis uses proteomics to identify early factors of long COVID
IsoPlexis has published a study in Cell, led by the Institute for Systems Biology and the Seattle COVID Consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as post-acute sequelae of COVID-19 (PASC) or long COVID. Read More
EpiCypher, New England Biolabs codevelop Cut&Run library prep kit
EpiCypher has entered into a partnership with New England Biolabs (NEB) to codevelop a first-in-class library prep kit specifically optimized for best performance with EpiCypher’s CUTANA Cut&Run epigenomic assays. Read More
New 'antibody-decorated nanocrystals' target cancer cells
Researchers have bioengineered a metal-organic framework antibody drug delivery system that has the potential to fast-track personalized therapies for cancer and other diseases. The findings were published December 7 in the journal Advanced Materials. Read More
New neoadjuvant platform helps inform combo immunotherapy selection for cancers
WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
